Stephanie Okey, Director at Crinetics Pharmaceuticals, Inc. (CRNX), sold 6,900 shares at $35.62 ($246K) on 2026-06-17, disclosed to the SEC on 2026-06-18.
Scheduled sale ($246k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.62 | 6,292 | $224K | 91.1% |
| 2 | $36.22 | 608 | $22K | 8.9% |
| Total | $35.67 avg | 6,900 | $246K | 100% |
| Filing → |
| CRNX | SELL | 2026-03-04 | $119K | — | Filing → |
| PTCT | SELL | 2025-03-17 | $270K | — | Filing → |
| CRNX | SELL | 2024-04-02 | $812K | — | Filing → |